Randomized, double blind trial of MP29-02 nasal spray compared to placebo, azelastine hydrochloride nasal spray, and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis.
Phase of Trial: Phase III
Latest Information Update: 09 Nov 2015
At a glance
- Drugs Azelastine; Azelastine/fluticasone-propionate; Fluticasone propionate
- Indications Seasonal allergic rhinitis
- Focus Registrational; Therapeutic Use
- 23 Oct 2015 According to the media release of Meda Pharmaceuticals, based on the data from this and other two trials (CTP: 37579 and 43617) Dymista nasal spray (azelastine hydrochloride/fluticasone propionate) was approved by Health Canada for the symptomatic treatment of moderate-to-severe seasonal allergic rhinitis.
- 06 Mar 2012 Results reporting the key secondary endpoint of the 12-hour reflective Total Ocular Symptom Score presented at the 68th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 05 Mar 2012 Results from this trial were presented at the American Academy of Allergy, Asthma and Immunology (AAAAI), according to a Meda media release
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History